• Profile

Ranitidine and risk of bladder and kidney cancer: A population-based cohort study

Cancer Epidemiology, Biomarkers & Prevention Nov 22, 2021

Nørgaard M, Andersen IT, Heide-Jørgensen U, et al. - Use of ranitidine was not associated with a substantial increase in bladder or kidney cancer occurrence.

  • Withdrawal of ranitidine in 2019 was because of high levels of N-nitrosodimethylamine, a probable human carcinogen.

  • This is a Danish nationwide cohort study including 31,393 initiators (adults 18 years or older) of ranitidine, 65,384 initiating other H2-blockers (H2-receptor antagonists), and 509,849 initiating proton pump inhibitors (PPI), to clarify risk of bladder and kidney cancer in ranitidine users.

  • Experts employed propensity scores for ranitidine use to calculate stabilized inverse probability of treatment (sIPT) weights as well as applied Cox regression to estimate crude and weighted HRs.

  • Relative to other H2-blockers, the crude HR for bladder cancer was estimated to be 1.33, but sIPT weighting attenuated this to 1.11.

  • The estimated weighted HR was 1.24 (95% CI: 1.04–1.48) vs PPI initiators.

  • The weighted HR for kidney cancer was 0.89 (95% CI: 0.72–1.10) vs users of H2-blockers and 0.87 (95% CI: 0.67–1.13) vs users of PPI.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen